Key result
Beta-interferon discontinuation after three years was significantly more frequent in patients with secondary progressive MS (23%) than in those with relapsing-remitting MS (14%, P=0.0003).
Why the study?
What are the frequency, timing, and reasons for discontinuing beta-interferon therapy in patients with multiple sclerosis?
Cohort (n=394)
No
What are the frequency, timing, and reasons for discontinuing beta-interferon therapy in patients with multiple sclerosis?
Absolute Event Rate: 23% vs 14%
p-value: p=0.0003
Beta-interferon discontinuation in multiple sclerosis occurs earlier when due to side effects and is more common in secondary progressive MS due to treatment failure.
No takes yet. Share an insight, caveat, or question.
Higher discontinuation in SPMS may prompt earlier therapy review; leaves open optimal switching strategies in progressive disease.
O’Rourke et al. (2005) conducted a cohort in Relapsing-remitting and secondary progressive multiple sclerosis (n=394). Beta-interferon (IFNB) in secondary progressive MS (SPMS) vs. Beta-interferon (IFNB) in relapsing-remitting MS (RRMS) was evaluated on IFNB stopping rate after three years of follow-up (p=0.0003). Beta-interferon discontinuation after three years was significantly more frequent in patients with secondary progressive MS (23%) than in those with relapsing-remitting MS (14%, P=0.0003).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: